Aim Immunotech Stock Performance
| AIM Stock | USD 0.13 0.01 8.33% |
The firm shows a Beta (market volatility) of -0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning AIM ImmunoTech are expected to decrease at a much lower rate. During the bear market, AIM ImmunoTech is likely to outperform the market. At this point, AIM ImmunoTech has a negative expected return of -0.66%. Please make sure to confirm AIM ImmunoTech's total risk alpha, as well as the relationship between the kurtosis and day median price , to decide if AIM ImmunoTech performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days AIM ImmunoTech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:44 | Dividend Date 2019-06-11 | Last Split Date 2019-06-11 |
1 | OBERON AIM VCT PLC UK Regulatory Announcement Appointment of auditor | 12/10/2024 |
2 | Acquisition by Bryan Nancy of 24452 shares of AIM ImmunoTech at 0.213 subject to Rule 16b-3 | 12/13/2024 |
3 | Acquisition by William Mitchell of 26305 shares of AIM ImmunoTech at 0.198 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Stewart Appelrouth of 1136 shares of AIM ImmunoTech at 16.72 subject to Rule 16b-3 | 01/08/2025 |
5 | Truv Integrates with Freddie Mac AIM Check API | 01/14/2025 |
6 | Investors Give Ai-Media Technologies Limited Shares A 27 percent Hiding | 02/03/2025 |
7 | AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIMs Ampligen and AstraZenecas FluMist to address the recent a... | 02/07/2025 |
8 | AIM ImmunoTech Releases Virtual Investor What This Means Segment | 02/11/2025 |
9 | Acquisition by Bryan Nancy of 43330 shares of AIM ImmunoTech at 0.1202 subject to Rule 16b-3 | 02/14/2025 |
10 | Disposition of 43330 shares by William Mitchell of AIM ImmunoTech at 0.1202 subject to Rule 16b-3 | 02/19/2025 |
11 | Insider Trading | 02/21/2025 |
12 | AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director | 02/26/2025 |
13 | Acquisition by Bryan Nancy of 38580 shares of AIM ImmunoTech at 0.135 subject to Rule 16b-3 | 02/28/2025 |
14 | Goodbody Enhances Portfolio Management Workflow with Adoption of Bloomberg AIM | 03/04/2025 |
15 | Acquisition by Thomas Equels of 50000 shares of AIM ImmunoTech at 0.1346 subject to Rule 16b-3 | 03/06/2025 |
| Begin Period Cash Flow | 27.1 M |
AIM |
AIM ImmunoTech Relative Risk vs. Return Landscape
If you would invest 22.00 in AIM ImmunoTech on December 10, 2024 and sell it today you would lose (9.00) from holding AIM ImmunoTech or give up 40.91% of portfolio value over 90 days. AIM ImmunoTech is generating negative expected returns assuming volatility of 6.4245% on return distribution over 90 days investment horizon. In other words, 57% of stocks are less volatile than AIM, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AIM ImmunoTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AIM ImmunoTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AIM ImmunoTech, and traders can use it to determine the average amount a AIM ImmunoTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1035
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AIM |
Estimated Market Risk
| 6.42 actual daily | 57 57% of assets are less volatile |
Expected Return
| -0.66 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AIM ImmunoTech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AIM ImmunoTech by adding AIM ImmunoTech to a well-diversified portfolio.
AIM ImmunoTech Fundamentals Growth
AIM Stock prices reflect investors' perceptions of the future prospects and financial health of AIM ImmunoTech, and AIM ImmunoTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AIM Stock performance.
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.84 | ||||
| Operating Margin | (128.26) % | ||||
| Current Valuation | 5.34 M | ||||
| Shares Outstanding | 68.75 M | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 3.14 X | ||||
| Price To Sales | 48.13 X | ||||
| Revenue | 202 K | ||||
| Gross Profit | 154 K | ||||
| EBITDA | (31.68 M) | ||||
| Net Income | (28.96 M) | ||||
| Cash And Equivalents | 27.05 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 718 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (21.27 M) | ||||
| Earnings Per Share | (0.47) X | ||||
| Market Capitalization | 9.14 M | ||||
| Total Asset | 19.38 M | ||||
| Retained Earnings | (409.51 M) | ||||
| Working Capital | 34.96 M | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
About AIM ImmunoTech Performance
By examining AIM ImmunoTech's fundamental ratios, stakeholders can obtain critical insights into AIM ImmunoTech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AIM ImmunoTech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3 K | -2.9 K | |
| Return On Tangible Assets | (1.53) | (1.45) | |
| Return On Capital Employed | (3.42) | (3.25) | |
| Return On Assets | (1.34) | (1.28) | |
| Return On Equity | (3.25) | (3.09) |
Things to note about AIM ImmunoTech performance evaluation
Checking the ongoing alerts about AIM ImmunoTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AIM ImmunoTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AIM ImmunoTech generated a negative expected return over the last 90 days | |
| AIM ImmunoTech has high historical volatility and very poor performance | |
| AIM ImmunoTech has some characteristics of a very speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 202 K. Reported Net Loss for the year was (28.96 M) with profit before taxes, overhead, and interest of 154 K. | |
| AIM ImmunoTech has about 27.05 M in cash with (21.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Thomas Equels of 50000 shares of AIM ImmunoTech at 0.1346 subject to Rule 16b-3 |
- Analyzing AIM ImmunoTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AIM ImmunoTech's stock is overvalued or undervalued compared to its peers.
- Examining AIM ImmunoTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AIM ImmunoTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AIM ImmunoTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AIM ImmunoTech's stock. These opinions can provide insight into AIM ImmunoTech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.